Literature DB >> 2321069

Clindamycin/primaquine therapy and secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS.

R Kay1, R E DuBois.   

Abstract

We found a program of intravenous and subsequent oral clindamycin, combined with oral primaquine, to be effective for Pneumocystis carinii pneumonia in nine patients with AIDS. The pneumonias were either primary or recurrent and sometimes severe, with cavity formation and/or pneumothorax. Maintenance therapy at lowered dose by mouth was effective in preventing recurrence in seven patients. One patient died of other opportunistic infections on day 24, and therapy was discontinued in another on day 11 because of skin rash. We conclude that clindamycin/primaquine is effective for therapy of P carinii pneumonia in patients with AIDS, as well as for long-term secondary prophylaxis at lowered dosage.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2321069     DOI: 10.1097/00007611-199004000-00010

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  9 in total

1.  Opportunistic infections in HIV-infected patients.

Authors:  S D Shafran
Journal:  Can J Infect Dis       Date:  1992-03

Review 2.  Pneumocystis carinii, an opportunist in immunocompromised patients.

Authors:  M S Bartlett; J W Smith
Journal:  Clin Microbiol Rev       Date:  1991-04       Impact factor: 26.132

Review 3.  Treatment of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 4.  Prevention of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 5.  Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia.

Authors:  H F Vöhringer; K Arastéh
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

6.  8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models.

Authors:  M S Bartlett; S F Queener; R R Tidwell; W K Milhous; J D Berman; W Y Ellis; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

7.  Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs.

Authors:  M C Broughton; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

8.  Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate.

Authors:  N P Dhammika Nanayakkara; Arba L Ager; Marilyn S Bartlett; Vanessa Yardley; Simon L Croft; Ikhlas A Khan; James D McChesney; Larry A Walker
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

Review 9.  Treatment and prophylaxis of Pneumocystis carinii pneumonia in AIDS patients.

Authors:  D Smith; B Gazzard
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.